Purdue Pharma lays off 350, cutting remainder of sales force

Purdue Pharma lays off 350, cutting remainder of sales force

Dive Brief: Purdue Pharma this week laid off about 350 employees, including the remainder of its sales force, as it attempts to move away from a business model built around the aggressive marketing of prescription opioids like its top-selling Oxycontin. The company, which remains in the spotlight for its alleged hand in contributing to an […]

Purdue Pharma Battling More States Over Opioid Crisis

Purdue Pharma Battling More States Over Opioid Crisis

Oxycontin maker Purdue Pharma has been in the hot seat when it comes to the opioid crisis, as some feel that the company deceptively marketed its prescription painkiller to generate sales, which led in part to the current opioid crisis. Lawsuits had been filed by sixteen states and Puerto Rico. In mid-May 2018, six additional […]

Five things for pharma marketers to know: Thursday, June 21, 2018

Five things for pharma marketers to know: Thursday, June 21, 2018

Copyright © 2018 Haymarket Media, Inc. All Rights Reserved This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media’s Privacy Policy and Terms & Conditions. Source link

Purdue Pharma used deceptive sales tactic for OxyContin after settlement, ex-sales rep says

Purdue Pharma used deceptive sales tactic for OxyContin after settlement, ex-sales rep says

Purdue Pharma laid off its entire sales team this week. Now only on “CBS This Morning,” a former Purdue sales representative reveals the drugmaker downplayed the dangers of opioids, even after pleading guilty to a felony charge of “misbranding.” Purdue’s 2007 settlement with the Justice Department included more than $630 million in fines.  But 24 […]

Your Daily Pharma Scoop: Anika Fails Trial, Kala's Upcoming Catalyst, Sarepta Surges

Your Daily Pharma Scoop: Anika Fails Trial, Kala's Upcoming Catalyst, Sarepta Surges

Analysis Focus: ANIK Anika Therapeutics (ANIK) announced failure of its candidate CINGAL to achieve primary endpoint in a Phase 3 clinical trial in knee osteoarthritis (‘OA). CINGAL could not succeed in showing a statistically significant reduction in knee pain. CINGAL is a combination anti-inflammatory formula that combines hyaluronic acid (‘HA) with a steroid (triamcinolone hexacetonide). […]

Exfoliative Dermatitis

Exfoliative Dermatitis

Exfoliative dermatitis is a skin condition in which the skin becomes inflamed (dermatitis) and the skin peels-off (exfoliation) over large areas of the body. The affected areas become reddened (erythema), accompanied by irritation and pain. This condition can occur due to pre-existing skin disorders, cancer, drug-induced (iatrogenic) or without any known cause (idiopathic). Generalized exfoliative […]

CASI Pharma (CASI) Enters Pact With Yiling Wanzhou International Pharmaceuticals For Entecavir And Cilostazol

CASI Pharma (CASI) Enters Pact With Yiling Wanzhou International Pharmaceuticals For Entecavir And Cilostazol

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here. CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients in the U.S., China and throughout the world, announces […]

Intec Pharma: Is It Time To Go Bottom Fishing?

Intec Pharma: Is It Time To Go Bottom Fishing?

Shares of Intec Pharma (NTEC) rose by over 50% shortly after I suggested readers pull the trigger after the secondary offering last August- from there the stock lost all signs of strength and is currently 22% in the red and trading near all-time lows. Chart Figure 1: NTEC daily advanced chart (Source: Finviz) Figure 2: […]

Purdue Pharma continued deceptive sales practices for OxyContin after 2007, whistleblower says

Purdue Pharma continued deceptive sales practices for OxyContin after 2007, whistleblower says

A former sales representative for Purdue Pharma tells CBS News the drug maker continued to engage in deceptive sales practices for its opiate painkiller OxyContin, later than the company previously acknowledged. In a 2007 settlement with the federal government, the company acknowledged it falsely promoted OxyContin as less addictive than its rivals. Purdue at the […]